Abbott
https://www.abbott.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Abbott
Japan’s New Infertility Coverage To Drive The Market
Japan's national health insurance scheme will reimburse infertility treatments from April 2022, in a bid to make the treatments more accessible to patients by effectively lowering the cost by 70%. The key strategic aim is to raise a low birth rate and the move is also set to substantially expand the market for such products for both domestic and foreign players.
Xtandi Petition Will Give Biden Administration Chance To Weigh In On Pricing, March-In Rights
Prostate cancer patients press HHS for administrative hearing on march-in rights for patents covering Astellas’ Xtandi. While previous efforts have failed, petitioners believe they may have a shot this time around given Biden Administration and HHS Secretary Becerra’s views on the issue.
Piramal Dreams Big, Wants To Be In Top Five India-Listed Pharma
Nandini Piramal, executive director of Piramal Enterprises, discusses how things have shaped the group's pharma business, its continuing appetite for acquisitions, efforts to de-risk the supply chain for key starting materials and the outsourcing "framework" deployed by industry.
Abbott Claims DexCom CGM Suits Renege On Tech-Sharing Agreement
Abbott says DexCom’s patent suits involve technology that was already the subject of a settlement, and raise venue questions.
Company Information
- Industry
-
Medical Devices
- Diagnostic Equipment & Supplies
- Monitoring Equipment & Devices
- Other Names / Subsidiaries
-
- Medscreen Ltd.